Clinical Trials Directory

Trials / Unknown

UnknownNCT04191265

Cardiotoxicity of Aluminum Phosphide Poisoning; Tropinin and CKmb as Early Biomarkers

Cardiotoxicity of Aluminum Phosphide Poisoning; Biochemical and Electrophysiological Studies and the Utility of Tropinin and CKmb as Early Biomarkers

Status
Unknown
Phase
Study type
Observational
Enrollment
60 (actual)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
Healthy volunteers

Summary

Aluminum phosphide (AlP) or rice tablet is a cheap pesticide. When it comes in contact with acid (gastric acid) or moisture, it releases phosphine (PH3) gas. The heart,lungs, liver are the main targets in acute Aluminum phosphide (AlP) poisoning. Most deaths occur due to cardiovascular toxicity.

Detailed description

Aluminium phosphide is a potent respiratory chain enzyme inhibitor. Its most important effect is the inhibition of cytochrome c oxidase. The inhibition of cytochrome c oxidase and other enzymes leads to the generation of superoxide radicals and cellular peroxides , and subsequent cellular injury through lipid peroxidation and other oxidant mechanisms. It stimulates the production of hydrogen peroxide and reactive oxygen species, malonyldialdehyde (MAD), increases superoxide dismutase and inhibits catalase, peroxidase and glutathione . Oxidative stress is one of the main mechanisms of action of aluminium phosphide toxicity

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTserum tropinin, serum CKmbearly detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock

Timeline

Start date
2019-12-05
Primary completion
2020-06-05
Completion
2020-06-05
First posted
2019-12-09
Last updated
2020-05-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04191265. Inclusion in this directory is not an endorsement.